New insider activity at Amylyx Pharmaceuticals Inc ( (AMLX) ) has taken place on March 6, 2025.
Co-CEO Justin B. Klee has sold 4,595 shares of Amylyx Pharmaceuticals Inc stock, amounting to $14,474. Similarly, Co-CEO Joshua B. Cohen has sold 4,595 shares of the same stock, totaling $14,520.
Recent Updates on AMLX stock
In recent developments, Amylyx Pharmaceuticals Inc. has faced significant risks related to its strategy of acquisitions and business combinations, particularly following the discontinuation of RELYVRIO/ALBRIOZA. The company has acquired assets from Eiger for avexitide development, but future acquisitions are contingent on suitable candidates and resources, posing challenges such as management distraction and financial strain. Despite these risks, Amylyx reported positive advancements in its clinical programs, notably the pivotal Phase 3 LUCIDITY trial for avexitide. Financially, the company ended 2024 with a solid cash reserve, bolstered by a $65.5 million public offering, extending its cash runway through 2026. However, it reported a net loss of $37.5 million for Q4 2024. The company also filed a $300 million mixed securities shelf, indicating strategic financial planning to support its pipeline and commercial preparations. Analysts have set an average price target implying significant upside potential, driven by the company’s robust pipeline and strategic initiatives, despite the inherent risks in clinical and regulatory processes.
More about Amylyx Pharmaceuticals Inc
YTD Price Performance: -23.02%
Average Trading Volume: 827,896
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $257.9M